Skip to main content
. Author manuscript; available in PMC: 2023 May 16.
Published in final edited form as: Nature. 2022 Nov 16;611(7937):780–786. doi: 10.1038/s41586-022-05438-x

Extended Data Fig. 1. Enterococcal abundance and dynamics during CDI.

Extended Data Fig. 1

(a) Enterococcal bacterial burdens (CFUs) from pediatric patients (black and gold = Vanderbilt University (median, n = 24 for Non-CDI controls; n = 34 for CDI, two-sided Mann-Whitney, P=0.004); blue and light blue = Children’s Hospital of Philadelphia (n = 19 for healthy; n = 20 for IBD + CDI, two-sided Mann-Whitney test, P=0.012). (b) Two-sided Spearman correlation between detected C. difficile and Enterococcus burdens in pediatric patients with IBD + CDI (Spearman ρ = 0.551; n = 19). (c) Bacterial burdens quantified from mice following treatment with cefoperazone (cef) or cef + vancomycin (vanc) (mean ± s.e.m., n = 10 mice/group). (d) Enterococcal CFUs over the course of CDI. Mice were infected with a toxin producing wild type strain (M7404 TcdA+TcdB+) or a toxin-null isogenic mutant (M7404 TcdA−TcdB−) (n = 5/group) (mean ± s.e.m. two-sided Mann-Whitney with Bonferroni-Dunn method for correction for multiple comparisons, corrected P values are in Supplementary Table 5).